Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Continues To Bank On Growth Of its Savella Medication for Fibromyalgia

This article was originally published in The Pink Sheet Daily

Executive Summary

With the only drug indicated solely for fibromyalgia, Forest expects Savella to help offset declining sales from its Lexapro antidepressant.

You may also be interested in...



Forest Should Conduct More Bystolic Studies For CHF Approval, Panel Says

An FDA panel decided that the agency should not approve Forest Laboratories' Bystolic (nebivolol) for chronic heart failure based on the current evidence, but suggested the drug could be approved for this added indication if the drug maker conducts a non-inferiority trial against other beta-blockers

Forest Should Conduct More Bystolic Studies For CHF Approval, Panel Says

An FDA panel decided that the agency should not approve Forest Laboratories' Bystolic (nebivolol) for chronic heart failure based on the current evidence, but suggested the drug could be approved for this added indication if the drug maker conducts a non-inferiority trial against other beta-blockers

Bystolic Advisory Committee: Trial Shortcomings Could Mean Tough Panel Review

Single pivotal trail for Forest's beta blocker may produce a skeptical audience on Jan. 11, when an FDA advisory committee evaluates the additional requested indication for chronic heart failure.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel